Biotech

A healthy workflow names the program hypothesis, maps preclinical and translational milestones to the next financing or partnering decision, and then builds clinical and regulatory readiness in parallel. The work gets expensive when those streams only meet at the deadline.

FDA and NIH material give the operating frame; scverse and related open tooling show how modern analysis work is actually being done. That combination is useful because it keeps the science and the operational path in the same conversation. The signals I care about are reproducibility of the evidence package, time from milestone to next decision, and readiness for study startup or scale-up. Those metrics reveal whether a team is generating knowledge or only generating slides.

A grounded version usually starts with three moves: Clarify whether the value is in the platform, the lead program, or the operating model.; Map preclinical and translational milestones to the next financing or partnering decision.; and Build trial operations and regulatory preparation in parallel with scientific execution.. Save the version that survived real constraints, not the one that only sounded elegant in a planning doc.

Useful operating references:
- NCATS translational science spectrum: ncats.nih.gov/translation/spectrum
Useful for keeping research work tied to concrete translational stages.
- NCBI Bookshelf: ncbi.nlm.nih.gov/books/
A deep public archive for primers, reference texts, and method overviews.
- scvi-tools: github.com/scverse/scvi-tools
Open source probabilistic tooling for single-cell and spatial omics work.